PharmiWeb.com - Global Pharma News & Resources

Pharmaco - Press Releases

Date Title Company
09-Jan-2025 BSI Software announces new Board of Directors BSI
09-Jan-2025 NICE RECOMMENDS LYNPARZA (OLAPARIB) TO TREAT GERMLINE BRCA-MUTATED HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER AFTER CHEMOTHERAPY IN ENGLAND AND WALES AstraZeneca
09-Jan-2025 Alchemab Therapeutics enters into collaboration with Lilly to discover, research and develop novel therapies for ALS Alchemab Therapeutics
09-Jan-2025 Astraveus Announces World First End-to-End Production of CAR-T Cells Using Microfluidic Technology Astraveus
09-Jan-2025 New Sarclisa subcutaneous formulation met co-primary endpoints in the IRAKLIA phase 3 study in multiple myeloma Sanofi
09-Jan-2025 Merck launches first-to-market, cyber-physical trust platform to tackle issues of product safety and counterfeiting Merck
09-Jan-2025 Biomarker and trial optimisation needed to drive R&D progress in Alzheimer’s and related disorders – ICON survey ICON
09-Jan-2025 Important milestone for Biotest: Biologics License Application for Fibrinogen submitted to the US Food and Drug Administration (FDA) Biotest AG
09-Jan-2025 Newron and Myung In Pharm announce license agreement for evenamide in South Korea Newron Pharmaceuticals S.p.A.
08-Jan-2025 Model N Appoints New Chief Executive Officer, Bret Connor Model N
08-Jan-2025 STRATEC TO PARTICIPATE IN THE 43RD ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE STRATEC SE
08-Jan-2025 PureTech to Present at 43rd Annual J.P. Morgan Healthcare Conference PureTech
08-Jan-2025 uniQure Announces Pricing of its Public Offering uniQure
08-Jan-2025 iTeos to Present at the 43rd Annual J.P. Morgan Healthcare Conference iTeos Therapeutics
08-Jan-2025 Formycon and Fresenius Kabi Canada receive Health Canada’s approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara® Formycon AG
08-Jan-2025 ProBioGen Expands Protein and Viral Manufacturing to Drive Continued Growth ProBioGen
08-Jan-2025 Angelini Ventures co-leads €20 million Series A financing in Neumirna Therapeutics to Develop Next-Generation RNA Therapeutics for Epilepsy and other Neurological Disorders Angelini Ventures
08-Jan-2025 Cambridge Cognition highlights positive CANTAB® results in research by Bristol Myers Squib Cambridge Cognition
08-Jan-2025 Experienced Industry Leader Dr. Joerg Moeller Appointed as Chief Executive Officer of Antag Therapeutics Antag Therapeutics
08-Jan-2025 Angelini Ventures co-leads €20 million Series A financing in Neumirna Therapeutics to Develop Next-Generation RNA Therapeutics for Epilepsy and other Neurological Disorders Angelini Ventures